World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

ANALYTICAL DEVELOPMENT, PREFORMULATION/FORMULATION, AND DRUGS’ SPECIFICATIONS: WHY THESE STEPS SHOULD BE CLOSELY CONNECTED?

Pascal St-Laurent* and François-Xavier Lacasse

ABSTRACT

Each new molecular entity (NME) or active pharmaceutical ingredient (API) is unique. Whether the molecule to be developed is a chemical (small molecule, peptide,..), a polymer, a biologic (polypeptide, protein, immunoglobulin,….) each of this entity will have to be developed under the same lot after lot irrespective of the scale in order to obtain the same physical, chemical and biological behaviors. Over the last decades, with the constant growth of small biotech companies came a paradigm shift in the business model. Since these companies were not necessarily strong enough (money and human resources) to launch a drug product, a new model was adopted to narrow down the risk. To summarize, ideally, the goal was to reach phase IIa clinical trial to generate clinical results (therapeutical exploration) and to license the molecule out to a partner, that would streamline the development through phase 3 and eventually commercialize the NME as a drug product. But, as mentioned, the above represents an ideal scenario. More than often, in the quest of the nanomolar efficiency, these young sponsors forgot the “druggability” and the overall reproducibility of their compounds, the reliability that analytical, preformulation/formulation development and specifications, even though they could have been surrounded by seasoned drug professionals referring to their proven track records, connected with reliable documentations such as pharmacopeia and guidelines. Authors of this short communication combine more than 50 years of drug development and will try to illustrate that science will never be better than regulatory requirements, regardless of drug indication.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR